J Cancer 2019; 10(18):4420-4429. doi:10.7150/jca.29898 This issue Cite

Research Paper

Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis

Yiyin Zhang1,2,3,4*, Jin Xu1,2,3,4*, Jie Hua1,2,3,4*, Jiang Liu1,2,3,4, Chen Liang1,2,3,4, Qingcai Meng1,2,3,4, Quanxing Ni1,2,3,4, Si Shi3✉, Xianjun Yu1,2,3,4✉

1. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong'An Road, Shanghai 200032, PR China
2. Department of Oncology, Shanghai Medical College, Fudan University, No. 270 Dong'An Road, Shanghai 200032, PR China
3. Shanghai Pancreatic Cancer Institute, No. 270 Dong'An Road, Shanghai 200032, PR China
4. Pancreatic Cancer Institute, Fudan University, No. 270 Dong'An Road, Shanghai 200032, PR China
*These authors contributed equally to this work

Citation:
Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, Ni Q, Shi S, Yu X. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. J Cancer 2019; 10(18):4420-4429. doi:10.7150/jca.29898. https://www.jcancer.org/v10p4420.htm
Other styles

File import instruction

Abstract

To evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NG) as a first-line treatment for advanced pancreatic cancer. A meta-analysis was performed to assess the impact on the objective response rate (ORR), survival rate and grade 3/4 adverse events. Of the 2,056 patients included from 26 studies, the median overall survival ranged from 6.9 months to 24.7 months, with a 1-year survival rate of 45.2% (95%CI: 35.8% -54.5%). The 6-month progression-free survival rate was 41.0% (95%CI: 30.5% - 51.4%), and the ORR was 31.6% (95%CI: 26.7% - 36.6%). Fifty locally advanced pancreatic cancer (LAPC) patients underwent surgery and had an R0 resection rate of 52.0%. No death was caused by toxicity, and 1,329 grade 3/4 adverse events were reported in 1,353 patients. NG has been proven to reduce tumours with an acceptable toxicity profile in metastatic pancreatic cancer. This analysis further demonstrates the efficacy and safety of NG for treating LAPC.

Keywords: nab-paclitaxel plus gemcitabine, advanced pancreatic cancer, meta-analysis.


Citation styles

APA
Zhang, Y., Xu, J., Hua, J., Liu, J., Liang, C., Meng, Q., Ni, Q., Shi, S., Yu, X. (2019). Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. Journal of Cancer, 10(18), 4420-4429. https://doi.org/10.7150/jca.29898.

ACS
Zhang, Y.; Xu, J.; Hua, J.; Liu, J.; Liang, C.; Meng, Q.; Ni, Q.; Shi, S.; Yu, X. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. J. Cancer 2019, 10 (18), 4420-4429. DOI: 10.7150/jca.29898.

NLM
Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, Ni Q, Shi S, Yu X. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. J Cancer 2019; 10(18):4420-4429. doi:10.7150/jca.29898. https://www.jcancer.org/v10p4420.htm

CSE
Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, Ni Q, Shi S, Yu X. 2019. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. J Cancer. 10(18):4420-4429.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image